CA
TOVX icon

Corrado Advisors’s Theriva Biologics TOVX Stock Holding History

Corrado Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1
Closed -$24K – 106
2016
Q1 		$24K Hold
1
– – 0.02% 92
2015
Q4 		$23K Buy
+1
New +$21.2K 0.01% 85

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Corrado Advisors's TOVX Position: Q2 2016 in Review

Corrado Advisors sold out of Theriva Biologics (TOVX) in Q2 2016, closing a stake of 1 share — an estimated $24K sold.

Corrado Advisors first reported a position in TOVX in Q4 2015 and held it in 2 quarters. The position peaked at $24K in Q1 2016. 61 funds tracked by Wall St. Rank hold TOVX as of Q2 2016.

  • Corrado Advisors reported no remaining Theriva Biologics position as of Q2 2016 after selling out during the quarter.
  • Corrado Advisors sold 1 Theriva Biologics share in Q2 2016, an estimated $24K.
  • Corrado Advisors first reported a position in Theriva Biologics in Q4 2015 and held it in 2 quarters.
  • Corrado Advisors's Theriva Biologics position peaked at $24K in Q1 2016.
  • 61 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2016.

Based on Corrado Advisors's 13F filing for Q2 2016, filed 8 Jul 2016.